UK's Institute of Cancer Research Taps Dotmatics' Software for Drug Discovery Work | GenomeWeb

Dotmatics said this week that the Institute of Cancer Research, London, has licensed Vortex, its data visualization and analysis tool, for use in cancer drug research and development efforts.

Julian Blagg, who heads ICR’s chemistry department and is the deputy director of its cancer therapeutics division, said that the institute selected Vortex, after internal testing, because of its "flexibility, ease of use and swift integration with our existing chemoinformatics data storage platform.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.